Esperion Therapeutis.Inc. buy nadine86
Summary
This prediction ended on 12.06.23 with a price of €1.29. With a performance of -6.13%, the BUY prediction by nadine86 finished with a loss. nadine86 has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Esperion Therapeutis.Inc. | 4.053% | 4.053% |
iShares Core DAX® | 0.000% | -2.064% |
iShares Nasdaq 100 | 0.626% | -2.884% |
iShares Nikkei 225® | 1.568% | -5.892% |
iShares S&P 500 | 0.334% | -2.281% |
Comments by nadine86 for this prediction
In the thread Trading Esperion Therapeutis.Inc.